A
Alcista
Alcista · 25%IKT
$2.41
Precio del escenario
$1.565
+0.090 (+5.74%)Al cierre
Loading chart…
- Máximo
- 1.600
- Apertura
- 1.560
- Precio medio ponderado por volumen
- 1.56
- Volumen
- 675.94K
- Capitalización
- 9.89M
- Mínimo
- 1.510
- Importe
- 1.05M
- EV/EBITDA, TTM
- 0.00
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Análisis de IA of Inhibikase Therapeutics Inc (IKT)
MantenerInhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.
Métricas de valoración
El PER previsto actual de Inhibikase Therapeutics Inc (IKT) es 0.00, frente a su media de 5 años de -2.42.
Escenarios de precio de Alphio AI para IKT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IKT en cartera
Cronología de eventos
Noticias
9.007-23NewsfilterInhibikase Receives Orphan Drug Designation
8.507-14seekingalphaInhibikase Therapeutics Sells 25M Shares for $50M
- 9.505-12seekingalpha
Inhibikase Therapeutics Q1 Earnings Beat Expectations
- 5.004-03Newsfilter
Inhibikase Grants Stock Options to New Employees Under Inducement Plan
- 9.503-26seekingalpha
Inhibikase Therapeutics Reports FY 2025 Financial Results
Preguntas frecuentes sobre IKT, respondidas por Alphio AI
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.